Latest News

Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.

New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.

Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.

With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.

Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.

A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.

Helicobacter pylori exposure could be associated with approximately 22% of colorectal cancer cases worldwide.

Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.

Pharmacists play a key role in guiding age- and risk-based vaccination decisions to protect against invasive and noninvasive disease.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

Machine-learning and multiple-imputation models could help researchers estimate missing baseline Eastern Cooperative Oncology Group performance status in advanced prostate cancer.

Gepotidacin and zoliflodacin show comparable efficacy to standard care for urogenital gonorrhea, offering promising alternatives given the recent rise in antimicrobial resistance.

At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.

Phase 3 HARMONi-2 interim analysis shows first bispecific PD-1/VEGF antibody outperforming standard immunotherapy in first-line NSCLC.

Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.

With nearly 8 in 10 older adults misusing at least 1 OTC product, clearer counseling and labels could close the gap.

Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.

The expanded approval of leniolisib makes it the first approved treatment for pediatric patients with activated phosphoinositide 3-kinase delta syndrome.

Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.

Contraceptive access gaps driven by federal rollbacks, provider shortages, and stalled state legislation could be narrowed by letting trained pharmacists prescribe birth control independently.

Cancer diagnoses among civilians exposed to 9/11 dust keep rising, with strained health programs struggling to meet growing needs.